Clinical-stage biotechnology company Accro Bioscience Inc announced on Monday the closing of its USD50m Series C financing.
The round was led by OrbiMed, with participation from TCG Crossover, LAV, Cenova Capital, and existing investors Shenzhen Capital Group, and Oriza Holdings.
Accro Bioscience plans to use the proceeds from the financing to fund the Phase IIb clinical trial of AC-101, an RIPK2 inhibitor, for the treatment of Ulcerative Colitis (UC), and other novel therapeutic candidates for inflammatory and autoimmune diseases.
Akeso reports results from Phase II trial of ligufalimab combination therapy in AML
Tenaya Therapeutics reports interim RIDGE-1 data showing reduced arrhythmia burden with TN-401
SN BioScience reports first patient dosed in global Phase 1b/2 clinical trial of SNB-101
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
AstraZeneca reports survival gains in Phase III bladder cancer trial
Ipsen presents Phase II corabotase data at SCALE 2026 symposium
SOPHiA GENETICS and Synnovis partner to expand NHS liquid biopsy testing
Voyager Technologies secures ISS mission management contract with Exobiosphere
WuXi Biologics named in 2026 Dow Jones Best-in-Class World Index and Emerging Markets Index
Clearway Health recognised with 2026 Great Place To Work Certification for fourth consecutive year
Servier's Emi-Le receives US FDA breakthrough therapy designation for adenoid cystic carcinoma
Insilico Medicine enters strategic collaboration agreement with Ribo
Bavarian Nordic secures USD97m US vaccine contract expansion and raises 2026 outlook